Cystatin C predicts cognitive decline in multiple system atrophy: A 1-year prospective cohort study

被引：3

作者：

Zhang, Lingyu ^{[1
,2
]}

Li, Ruicen ^{[1
]}

Hou, Yanbing ^{[2
]}

Cao, Bei ^{[2
]}

Wei, Qianqian ^{[2
]}

Ou, Ruwei ^{[2
]}

Liu, Kuncheng ^{[2
]}

Lin, Junyu ^{[2
]}

Yang, Tianmi ^{[2
]}

Xiao, Yi ^{[2
]}

Huang, Wenxia ^{[1
]}

Shang, Huifang ^{[2
]}

机构：

[1] Sichuan Univ, West China Hosp, Hlth Management Ctr, Gen Practice Med Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Rare Dis Ctr, Dept Neurol,Lab Neurodegenerat Disorders, Chengdu, Peoples R China

来源：

FRONTIERS IN AGING NEUROSCIENCE | 2022年 / 14卷

关键词：

multiple system atrophy; cystatin C; cognitive decline; prospective study; movement disorder; PARKINSONS-DISEASE; IMPAIRMENT; VALIDATION; STATEMENT; PATHOLOGY;

D O I：

10.3389/fnagi.2022.1069837

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

BackgroundAccumulating evidence has suggested that cystatin C is associated with cognitive impairment in patients with neurodegenerative diseases. However, the association between cystatin C and cognitive decline in patients with multiple system atrophy (MSA) remains largely unknown. ObjectivesThe objective was to determine whether cystatin C was independently associated with cognitive decline in patients with early-stage MSA. MethodsPatients with MSA underwent evaluation at baseline and the 1-year follow-up. Cognitive function was evaluated with Montreal cognitive assessment (MoCA). Changes in the MoCA score and the absolute MoCA score at the 1-year assessment were considered the main cognitive outcome. The cystatin C concentrations in patients with MSA and age, sex, and body mass index matched-healthy controls (HCs) were measured. A multiple linear regression model was used to test the association between cystatin C and cognitive decline. ResultsA total of 117 patients with MSA and 416 HCs were enrolled in the study. The cystatin C levels were significantly higher in patients with MSA than in HCs (p < 0.001). Cystatin C levels were negatively correlated with MoCA score at baseline and at 1-year follow-up. Multiple linear regression model adjusted for potential confounders showed that baseline cystatin C levels were significantly associated with the MoCA score (p = 0.004) or change in the MoCA score (p = 0.008) at 1-year follow-up. ConclusionOur results suggested that cystatin C may serve as a potential biomarker of cognitive decline in patients with early-stage MSA.

引用

页数：8